SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NexStar Pharm(NXTR)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: james who wrote (258)1/18/1998 12:25:00 AM
From: james  Read Replies (1) of 328
 
The most interesting aspect of nxtr's selex tech is quoted from the pnas paper:

<< It is not uncommon for a winning ligand from SELEX to have a nanomolar Kd when the target is a professional nucleic acid binding protein, while we have seen many picomolar Kd values for other protein targets. >>

PICOMOLAR compounds are rare, sort of compounds of a life time for researchers in drug discovery business. selex achieves this easily in that its starting libraries are HUGE & RANDOM. Most pharms compound libraries are only a tiny fraction of selex, & they are not random. So the chance of finding a winning drug candidate by selex in short period of time is much higher. Just interesting, interesting...................
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News